Sees FY25 gross margin 83%-85%. Sees positive adjusted EBITDA and cash flow in each quarter of 2025. Delcath Systems (DCTH) announced full year 2025 financial guidance and its intention to enter into a Medicaid National Drug Rebate Agreement to expand patient access.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DCTH:
- Delcath Systems Shareholders Approve Key Amendments at Meeting
- Delcath Systems: Strong Revenue Growth and Strategic Expansion Drive Buy Rating
- Delcath Systems Reports Strong Q1 2025 Growth
- Delcath Systems’ Earnings Call Highlights Growth and Challenges
- Delcath Systems reports Q1 EPS 3c, consensus 3c